Status:
COMPLETED
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
1-17 years
Phase:
PHASE3
Brief Summary
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
Eligibility Criteria
Inclusion
- Patients must complete the 16 Week double-blind efficacy study A1481131.
Exclusion
- Any patient who did not complete Study A1481131.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT00159874
Start Date
January 1 2004
End Date
December 1 2012
Last Update
February 1 2021
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Palo Alto, California, United States, 34304
2
Pfizer Investigational Site
Palo Alto, California, United States, 94305
3
Pfizer Investigational Site
Stanford, California, United States, 94305
4
Pfizer Investigational Site
Aurora, Colorado, United States, 80045